Back to Journals » Drug Design, Development and Therapy » Volume 10

Spotlight on grazoprevir—elbasvir once-daily combination and its potential in the treatment of hepatitis C

Authors Suraweera D, Weeratunga A, Saab S

Received 30 January 2016

Accepted for publication 26 February 2016

Published 29 June 2016 Volume 2016:10 Pages 2119—2127


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Wei Duan

Duminda Suraweera,1 Ashley N Weeratunga,2 Sammy Saab3

1Department of Medicine, Olive-View Medical Center, Sylmar, CA, 2Department of Medicine, Creighton University School of Medicine, Omaha, NE, 3Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA

Abstract: Chronic hepatitis C virus (HCV) infection is a leading cause of health care utilization in the USA. Incidence of cirrhosis from HCV is expected to rise in the near future, further increasing this burden. There is a high medical need for effective, tolerable, safe, all-oral, short-duration therapy. To this end, several new direct-acting antiviral agents have been developed and have shown excellent sustained virologic response rates. However, patients who have previously failed treatment or who have developed cirrhosis, renal failure, or human immunodeficiency virus coinfection remain difficult-to-treat subgroups. An all-oral agent that is effective in many of these subgroups would simplify treatment of HCV greatly. Here we review currently available data on the efficacy, treatment duration, tolerability, and safety of combination of grazoprevir and elbasvir.

Keywords: hepatitis C, antiviral therapy, grazoprevir, elbasvir

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]